NCT06193486 2026-03-31
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
24 trialsNCT06401980 2026-03-30
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05125016 2026-02-27
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06533644 2026-02-27
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.
Phase 2 Recruiting
NCT07244341 2026-02-04
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT06492122 2026-01-29
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06514521 2025-12-30
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
NCT06380738 2025-12-26
PROceed
AstraZeneca
Recruiting
NCT06155084 2025-12-22
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Hinova Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06228053 2025-12-22
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT06568562 2025-12-09
PRO-XL
University of Utah
Phase 2 Recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT05613894 2025-10-31
CaboLu
University of Utah
Phase 1 Recruiting
NCT06031805 2025-10-28
PROWESs
AstraZeneca
Recruiting
NCT05603559 2025-10-03
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT05116579 2024-09-05
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Sun Yat-sen University
Recruiting
NCT06529549 2024-07-31
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sun Yat-sen University
Recruiting
NCT05613738 2024-07-10
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT05458544 2024-04-29
LUCIDA
FutureChem
Phase 1/2 Recruiting